
|Articles|May 28, 2015
- Genitourinary (Issue 2)
- Issue 2
Use of ARN-509 in Prostate Cancer
Author(s)Charles J. Ryan, MD
Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.
Advertisement
Articles in this issue
over 10 years ago
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPCover 10 years ago
Study Illuminates Role of AR-V7 in Carcinogenesisover 10 years ago
PSA Screening Drops 50% Following USPSTF Recommendationover 10 years ago
Urine-Based Diagnostic Effectively Identifies Prostate Cancerover 10 years ago
Trends in PSA Utilization in Primary Care Physiciansover 10 years ago
AR-V7 as a Biomarker in CRPCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
4
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
5






































